Anna Licata

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7364255/publications.pdf

Version: 2024-02-01

85 papers 4,040 citations

30 h-index 62 g-index

85 all docs 85 docs citations

85 times ranked 5751 citing authors

#	Article	IF	CITATIONS
1	Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut, 2004, 53, 925-930.	12.1	490
2	Competing risks and prognostic stages of cirrhosis: a 25â€year inception cohort study of 494 patients. Alimentary Pharmacology and Therapeutics, 2014, 39, 1180-1193.	3.7	389
3	Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. Gastroenterology, 2018, 155, 411-421.e4.	1.3	291
4	Hepatitis C Virus Infection Is Associated With IncreasedÂCardiovascular Mortality: A Meta-Analysis of Observational Studies. Gastroenterology, 2016, 150, 145-155.e4.	1.3	201
5	Insulin Resistance and Diabetes Increase Fibrosis in the Liver of Patients With Genotype 1 HCV Infection. American Journal of Gastroenterology, 2008, 103, 1136-1144.	0.4	170
6	Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. Journal of Hepatology, 2019, 71, 265-273.	3.7	138
7	Carotid atherosclerosis and chronic hepatitis C: A prospective study of risk associations. Hepatology, 2012, 55, 1317-1323.	7.3	113
8	Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study. Journal of Hepatology, 2005, 42, 535-540.	3.7	101
9	Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. Journal of Hepatology, 2018, 69, 18-24.	3.7	98
10	When and how to treat acute hepatitis C?. Journal of Hepatology, 2003, 39, 1056-1062.	3.7	94
11	IL-10 and TNF-α polymorphisms and the recovery from HCV infection. Human Immunology, 2003, 64, 674-680.	2.4	84
12	Oxidative stress inhibits IFN-α-induced antiviral gene expression by blocking the JAK–STAT pathway. Journal of Hepatology, 2006, 45, 271-279.	3.7	83
13	The impact of radiotherapy on survival in resectable gastric carcinoma: A meta-analysis of literature data. Cancer Treatment Reviews, 2007, 33, 729-740.	7.7	83
14	Non invasive tools for the diagnosis of liver cirrhosis. World Journal of Gastroenterology, 2014, 20, 18131.	3.3	76
15	Adverse drug reactions and organ damage: The liver. European Journal of Internal Medicine, 2016, 28, 9-16.	2.2	74
16	Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems. Alimentary Pharmacology and Therapeutics, 2008, 28, 62-75.	3.7	69
17	Herbal hepatotoxicity: a hidden epidemic. Internal and Emergency Medicine, 2013, 8, 13-22.	2.0	61
18	PNPLA3 GG Genotype and Carotid Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease. PLoS ONE, 2013, 8, e74089.	2.5	59

#	Article	IF	CITATIONS
19	Inflammation and Aortic Stiffness: An Individual Participant Data Metaâ€Analysis in Patients With Inflammatory Bowel Disease. Journal of the American Heart Association, 2017, 6, .	3.7	58
20	Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference. Digestive and Liver Disease, 2016, 48, 455-467.	0.9	57
21	Central obesity and hypertensionThe role of plasma endothelin. American Journal of Hypertension, 1996, 9, 1186-1191.	2.0	56
22	Retinolâ€binding protein 4: A new marker of virusâ€induced steatosis in patients infected with hepatitis c virus genotype 1. Hepatology, 2008, 48, 28-37.	7. 3	55
23	Genetic association of interleukin-6 polymorphism (-174 G/C) with chronic liver diseases and hepatocellular carcinoma. World Journal of Gastroenterology, 2013, 19, 2449.	3.3	53
24	Clinical implications of the hyperdynamic syndrome in cirrhosis. European Journal of Internal Medicine, 2014, 25, 795-802.	2.2	48
25	Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: A retrospective cohort study. Digestive and Liver Disease, 2014, 46, 1116-1120.	0.9	44
26	Is Transient Elastography Needed for Noninvasive Assessment of High-Risk Varices? The REAL Experience. American Journal of Gastroenterology, 2019, 114, 1275-1282.	0.4	41
27	Can chemotherapy concomitantly delivered with radiotherapy improve survival of patients with resectable rectal cancer? A meta-analysis of literature data. Cancer Treatment Reviews, 2010, 36, 539-549.	7.7	37
28	Liver Function Test Abnormalities in Patients with Inflammatory Bowel Diseases: A Hospital-based Survey. Clinical Medicine Insights Gastroenterology, 2014, 7, CGast.S13125.	1.0	34
29	Hepatitis delta infection in Italian patients: towards the end of the story?. Infection, 2017, 45, 277-281.	4.7	34
30	A focus on epidemiology of drug-induced liver injury: analysis of a prospective cohort. European Review for Medical and Pharmacological Sciences, 2017, 21, 112-121.	0.7	34
31	Rivaroxaban-induced hepatotoxicity: review of the literature and report of new cases. European Journal of Gastroenterology and Hepatology, 2018, 30, 226-232.	1.6	33
32	Hyperferritinemia is a risk factor for steatosis in chronic liver disease. World Journal of Gastroenterology, 2009, 15, 2132.	3.3	32
33	Early carotid atherosclerosis and cardiac diastolic abnormalities in hypertensive subjects. Journal of Human Hypertension, 2004, 18, 201-205.	2.2	30
34	Clinical course and outcomes of drug-induced liver injury: Nimesulide as the first implicated medication. Digestive and Liver Disease, 2010, 42, 143-148.	0.9	30
35	Copper/MYC/CTR1 interplay: a dangerous relationship in hepatocellular carcinoma. Oncotarget, 2018, 9, 9325-9343.	1.8	30
36	Fecal Calprotectin in Clinical Practice. Journal of Clinical Gastroenterology, 2012, 46, 504-508.	2.2	29

#	Article	IF	Citations
37	Clinical course and prognostic factors of hepatorenal syndrome: A retrospective single-center cohort study. World Journal of Hepatology, 2013, 5, 685.	2.0	29
38	Elderly Onset Celiac Disease: A Narrative Review. Clinical Medicine Insights Gastroenterology, 2016, 9, CGast.S38454.	1.0	28
39	Heredity and obesity-associated hypertension: impact of hormonal characteristics and left ventricular mass. Journal of Hypertension, 1995, 13, 611-618.	0.5	27
40	NT Pro BNP Plasma Level and Atrial Volume Are Linked to the Severity of Liver Cirrhosis. PLoS ONE, 2013, 8, e68364.	2.5	26
41	Characteristics of liver cirrhosis in Italy: Evidence for a decreasing role of HCV aetiology. European Journal of Internal Medicine, 2017, 38, 68-72.	2.2	23
42	Expression of Cytokeratin 7 and 20 in Pathological Conditions of the Bile Tract. Pathology Research and Practice, 2003, 199, 65-70.	2.3	22
43	Acute polymyositis during treatment of acute hepatitis C with pegylated interferon alpha-2b. Digestive and Liver Disease, 2005, 37, 882-885.	0.9	22
44	Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: A meta-analysis. Journal of Hepatology, 2009, 51, 675-681.	3.7	22
45	Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection. Antiviral Therapy, 2009, 14, 631-639.	1.0	22
46	Left ventricular filling abnormalities and obesity-associated hypertension: relationship with overproduction of circulating transforming growth factor \hat{l}^21 . Journal of Human Hypertension, 2005, 19, 543-550.	2.2	21
47	Acute hepatitis C: In search of the optimal approach to cure. Hepatology, 2006, 43, 221-224.	7.3	21
48	Clinical Trial: Highâ€dose furosemide plus smallâ€volume hypertonic saline solutions vs. repeated paracentesis as treatment of refractory ascites. Alimentary Pharmacology and Therapeutics, 2009, 30, 227-235.	3.7	20
49	Treatment of hepatitis C: critical appraisal of the evidence. Expert Opinion on Pharmacotherapy, 2005, 6, 399-408.	1.8	18
50	Fluoroquinolone-induced liver injury: three new cases and a review of the literature. European Journal of Clinical Pharmacology, 2012, 68, 525-532.	1.9	18
51	The Role of Vitamin Deficiency in Liver Disease: To Supplement or Not Supplement?. Nutrients, 2021, 13, 4014.	4.1	18
52	Expansion of specific $\hat{l}\pm\hat{l}^2+$ T-cell subsets in the myocardium of patients with myocarditis and idiopathic dilated cardiomyopathy associated with Coxsackievirus B infection. Human Immunology, 2003, 64, 194-210.	2.4	17
53	Plasma adiponectin: A contributing factor for cardiac changes in visceral obesity-associated hypertension. Blood Pressure, 2014, 23, 147-153.	1.5	17
54	Insulin-resistance HCV infection-related affects vascular stiffness in normotensives. Atherosclerosis, 2015, 238, 108-112.	0.8	17

#	Article	IF	CITATIONS
55	Analysis of TCR \hat{V}^2 Repertoire and Cytokine Gene Expression in Patients with Idiopathic Dilated Cardiomyopathy. Journal of Autoimmunity, 2001, 16, 3-13.	6.5	16
56	Serum BLyS/BAFF predicts the outcome of acute hepatitis C virus infection. Journal of Viral Hepatitis, 2009, 16, 397-405.	2.0	16
57	Subclinical cardiovascular damage in patients with <scp>HCV</scp> cirrhosis before and after treatment with direct antiviral agents: a prospective study. Alimentary Pharmacology and Therapeutics, 2018, 48, 740-749.	3.7	16
58	Clinical course and management of acute and chronic viral hepatitis during pregnancy. Journal of Viral Hepatitis, 2015, 22, 515-523.	2.0	15
59	The Changing Epidemiology of Hepatocellular Carcinoma :  Experience of a Single Center. BioMed Research International, 2020, 2020, 1-9.	1.9	15
60	SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 2022, 23, 3668.	4.1	14
61	Surveillance Program for Diagnosis of HCC in Liver Cirrhosis: Role of Ultrasound Echo Patterns. BioMed Research International, 2017, 2017, 1-8.	1.9	13
62	Serology in adults with celiac disease: limited accuracy in patients with mild histological lesions. Internal and Emergency Medicine, 2012, 7, 337-342.	2.0	12
63	Cardiac involvement in patients with cirrhosis. Journal of Cardiovascular Medicine, 2016, 17, 26-36.	1.5	12
64	Small-Volume Hypertonic Saline Solution and High-Dosage Furosemide in the Treatment of Refractory Congestive Heart Failure. Clinical Drug Investigation, 2000, 19, 9-13.	2.2	11
65	Relationship between circulating E-selectin, DD genotype of angiotensin-converting-enzyme, and cardiovascular damage in central obese subjects. Metabolism: Clinical and Experimental, 2003, 52, 999-1004.	3.4	11
66	Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESISTâ€HCV cohort. Journal of Viral Hepatitis, 2021, 28, 1190-1199.	2.0	11
67	Liver injury, SARS OVâ€2 infection and COVIDâ€19: What physicians should really know?. GastroHep, 2021, 3, 121-130.	0.6	11
68	Case report: acute portal vein thrombosis associated with acute cytomegalovirus infection in an immunocompetent adult. Journal of Ultrasound, 2017, 20, 161-165.	1.3	10
69	C4BQ0: a genetic marker of familial HCV-related liver cirrhosis. Digestive and Liver Disease, 2004, 36, 471-477.	0.9	9
70	Nontumorous Portal Vein Thrombosis in Liver Cirrhosis: Possible Role of \hat{l}^2 -Blockers. Medical Principles and Practice, 2018, 27, 466-471.	2.4	9
71	Outcome predictors in SARS-CoV-2 disease (COVID-19): The prominent role of IL-6 levels and an IL-6 gene polymorphism in a western Sicilian population. Journal of Infection, 2022, 85, 174-211.	3.3	9
72	Weight-loss supplementation and acute liver failure: the case of Garcinia Cambogia. Internal and Emergency Medicine, 2018, 13, 833-835.	2.0	6

#	Article	IF	Citations
73	Genetic Predisposition to Thrombophilia in Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 2011, 45, e25-e29.	2.2	4
74	Renal function is impaired in normotensive chronic HCV patients: role of insulin resistance. Internal and Emergency Medicine, 2016 , 11 , $553-559$.	2.0	4
75	Sympathovagal balance and 1-h postload plasma glucose in normoglucose tolerant hypertensive patients. Acta Diabetologica, 2016, 53, 41-47.	2.5	3
76	Pancreatic cancer: risk and preventive factors. Internal and Emergency Medicine, 2018, 13, 321-323.	2.0	3
77	Is vitamin D deficiency predictor of complications development in patients with HCV-related cirrhosis?. Internal and Emergency Medicine, 2019, 14, 735-737.	2.0	3
78	Comorbidities impact and de-prescribing in elderly with HCV-related liver disease: analysis of a prospective cohort. Internal and Emergency Medicine, 2022, 17, 43-51.	2.0	3
79	Optimizing diagnostic approach to drug-induced liver injury. Italian Journal of Medicine, 2018, 12, 180-189.	0.3	2
80	Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort. Antiviral Therapy, 2020, 25, 73-81.	1.0	2
81	A patient with acute hepatitis C and possible IFN toxicity. Digestive and Liver Disease, 2003, 35, 372-373.	0.9	1
82	Waiting-Time and Quality of Care Deserved to Patients with Early Stage Hepatocellular Carcinoma Undergoing RFA Treatment. Annals of Hepatology, 2017, 16, 699-701.	1.5	1
83	Efficacy of 8 weeks elbasvir/grazoprevir regimen for naĀ ve-genotype 1b, HCV infected patients with or without glucose abnormalities: Results of the EGG18 study. Digestive and Liver Disease, 2022, 54, 1117-1121.	0.9	1
84	Considerations regarding the alleged association between Herbalife products and cases of hepatotoxicity: a rebuttal. Internal and Emergency Medicine, 2014, 9, 601-602.	2.0	0
85	Letter: effect of HCV eradication on cardiovascular disease—Authors' reply. Alimentary Pharmacology and Therapeutics, 2018, 48, 1169-1170.	3.7	0